1. Home
  2. KLTR vs SGMT Comparison

KLTR vs SGMT Comparison

Compare KLTR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaltura Inc.

KLTR

Kaltura Inc.

HOLD

Current Price

$1.71

Market Cap

238.4M

Sector

Technology

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.00

Market Cap

238.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLTR
SGMT
Founded
2006
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
238.4M
238.7M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
KLTR
SGMT
Price
$1.71
$6.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$3.50
$29.71
AVG Volume (30 Days)
348.9K
626.9K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$180,921,000.00
N/A
Revenue This Year
$3.10
N/A
Revenue Next Year
$1.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.88
N/A
52 Week Low
$1.36
$1.73
52 Week High
$2.82
$11.41

Technical Indicators

Market Signals
Indicator
KLTR
SGMT
Relative Strength Index (RSI) 55.78 38.86
Support Level $1.64 $5.80
Resistance Level $1.72 $6.33
Average True Range (ATR) 0.09 0.42
MACD 0.01 0.03
Stochastic Oscillator 63.46 21.46

Price Performance

Historical Comparison
KLTR
SGMT

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: